Literature DB >> 19886718

Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.

Celina G Kleer1.   

Abstract

This case presentation reviews the histologic distinction between pure medullary carcinoma and breast carcinomas with medullary-like features. This particular case prompts us to analyze the relationship among medullary carcinoma, basal-like breast carcinomas and carcinomas associated with germline BRCA1 mutations. In addition to now well-defined features, such as expression of high-molecular-weight cytokeratins and EGFR (epidermal growth factor receptor), basal-like tumors have a deficiency or dysfunction of BRCA1. This association in part explains the histologic features of BRCA1-associated breast cancers. Recent studies in our laboratory demonstrate that BRCA1 protein is regulated by a recently described gene, EZH2. These concepts illustrate the important relationships among histopathologic features; genomic profile; single gene abnormalities, such as BRCA1 and EZH2; and growth regulation in this subset of breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19886718      PMCID: PMC5058332          DOI: 10.5858/133.11.1822

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  16 in total

1.  Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.

Authors:  S A Vaziri; L M Krumroy; P Elson; G T Budd; G Darlington; J Myles; R R Tubbs; G Casey
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

2.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

3.  Concordance among gene-expression-based predictors for breast cancer.

Authors:  Cheng Fan; Daniel S Oh; Lodewyk Wessels; Britta Weigelt; Dimitry S A Nuyten; Andrew B Nobel; Laura J van't Veer; Charles M Perou
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

4.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.

Authors:  François Bertucci; Pascal Finetti; Nathalie Cervera; Emmanuelle Charafe-Jauffret; Emilie Mamessier; José Adélaïde; Stéphane Debono; Gilles Houvenaeghel; Dominique Maraninchi; Patrice Viens; Colette Charpin; Jocelyne Jacquemier; Daniel Birnbaum
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

5.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

6.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

7.  The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.

Authors:  William D Foulkes; Jean-Sébastien Brunet; Ingunn M Stefansson; Oddbjørn Straume; Pierre O Chappuis; Louis R Bégin; Nancy Hamel; John R Goffin; Nora Wong; Michel Trudel; Linda Kapusta; Peggy Porter; Lars A Akslen
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

8.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Authors:  Cornelia Liedtke; Chafika Mazouni; Kenneth R Hess; Fabrice André; Attila Tordai; Jaime A Mejia; W Fraser Symmans; Ana M Gonzalez-Angulo; Bryan Hennessy; Marjorie Green; Massimo Cristofanilli; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2008-02-04       Impact factor: 44.544

9.  Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.

Authors:  Sunil R Lakhani; Jorge S Reis-Filho; Laura Fulford; Frederique Penault-Llorca; Marc van der Vijver; Suzanne Parry; Timothy Bishop; Javier Benitez; Carmen Rivas; Yves-Jean Bignon; Jenny Chang-Claude; Ute Hamann; Cees J Cornelisse; Peter Devilee; Matthias W Beckmann; Carolin Nestle-Krämling; Peter A Daly; Neva Haites; Jenny Varley; Fiona Lalloo; Gareth Evans; Christine Maugard; Hanne Meijers-Heijboer; Jan G M Klijn; Edith Olah; Barry A Gusterson; Silvana Pilotti; Paolo Radice; Siegfried Scherneck; Hagay Sobol; Jocelyne Jacquemier; Teresa Wagner; Julian Peto; Michael R Stratton; Lesley McGuffog; Douglas F Easton
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

Review 10.  Triple negative tumours: a critical review.

Authors:  J S Reis-Filho; A N J Tutt
Journal:  Histopathology       Date:  2008-01       Impact factor: 5.087

View more
  6 in total

Review 1.  Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Konstantinos Nikolettos; Dimitrios Dimitroulis; Evangelos Diamantis; Paraskevi Farmaki; Alexandros Patsouras; Errika Voutyritsa; Athanasios Syllaios; Constantinos G Zografos; Efstathios A Antoniou; Nikos Nikolettos; Alkiviadis Kostakis; Konstantinos Kontzoglou; Dimitrios Schizas; Afroditi Nonni
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.

Authors:  Yaser R Hussein; Anil K Sood; Sudeshna Bandyopadhyay; Bassam Albashiti; Assaad Semaan; Zeina Nahleh; Juwon Roh; Hee Dong Han; Gabriel Lopez-Berestein; Rouba Ali-Fehmi
Journal:  Hum Pathol       Date:  2012-03-19       Impact factor: 3.466

3.  Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer.

Authors:  Sotirios Lakis; Vassiliki Kotoula; Georgia-Angeliki Koliou; Ioannis Efstratiou; Sofia Chrisafi; Alexios Papanikolaou; Pantelis Zebekakis; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

4.  DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.

Authors:  Mohammed Aleskandarany; Daniela Caracappa; Christopher C Nolan; R Douglas Macmillan; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Breast Cancer Res Treat       Date:  2015-02-19       Impact factor: 4.872

5.  Fine-Needle Cytological Characteristics of Carcinoma Breast with Medullary or Medullary-like Features Masquerading as Dendritic Reticulum Cell Sarcoma: An Attempt to Explore the Reasons for Erroneous Cytologic Interpretation.

Authors:  Dilip K Das; Shahed K Pathan; Zafar A Sheikh; Mrinmay K Mallik; Bency John; Fatma Mothaffer
Journal:  J Cytol       Date:  2020-04-14       Impact factor: 1.000

6.  Hormone Receptor Status May Impact the Survival Benefit Between Medullary Breast Carcinoma and Atypical Medullary Carcinoma of the Breast: A Population-Based Study.

Authors:  Wenxing Qin; Feng Qi; Mengzhou Guo; Liangzhe Wang; Yuan-Sheng Zang
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.